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ABSTRACT
Objectives: To determine the relative frequency of acute radiation morbidity and their 
perceived effect on quality of life among head and neck cancer patients treated with 
radical radiotherapy. 
Design: A cross-sectional study.
Setting: Kenyatta National Hospital, Nairobi. 
Subjects: Thirty eight patients comprising 28 males and 10 females with ages ranging 
between 21 and 69 years were evaluated. 
Results:  Most of the tumours occurred in the nasopharynx (38.6%). The rest of the 
tumours were equally divided between the oral cavity and larynx (31.6%). All tumours 
except  two were carcinomas. The two exceptions were a glomus tumour and a malignant 
melanoma. The patients had received doses of radiotherapy ranging between 58.5 Grey 
and 75.5 Grey. Of the 38 patients, 22 (53%) completed their treatment in the prescribed 
time while 16 (47%) had treatment interruption on account of radiation morbidity. The 
cumulative radiation done at the time of interruption ranged between 20 and 46 Grey. 
The most frequent symptom was dryness of the mouth while the most troublesome 
symptom was difficulty in tasting foods. The quality of life (QOL) did not vary by 
age, gender or tumour site. Patients who had treatment interruption had a better QOL 
than those who did not. 
Conclusion: This study provides information that should aid in communicating with 
the head and neck cancer patients scheduled for radiotherapy and in the design of 
preventive and interventional strategies aimed at enhancing patient support and 
rehabilitation. 
INTRODUCTION
Despite advances in diagnostic and treatment 
techniques the cure rates for head and neck cancers 
have remained unchanged in the last 50 years with 
the five year survival rates stabilising at about 50% 
(1, 2). In those patients who survive and become 
disease-free intense treatment may lead to physical 
and/or psychosocial disabilities (3, 4). This lack of 
progress and potential for morbidity associated with 
treatment has led head and neck cancer researchers 
to broaden the scope of their agenda to include 
investigations of health related QOL as a measure of 
outcome (5). QOL is particularly relevant for patients 
with head and neck cancer because social interaction 
and emotional expression depends, to a great extent, 
on the structure and functional integrity of the head 
and neck region (6). It is, therefore, of great clinical 
interest to determine the manner in which patients 
perceive and cope with these treatment-associated 
morbidities in order to assess the degree of treatment 
success and rehabilitation needs (7). The aim of this 
study was to determine the frequency and severity of 
radiation morbidity and their perceived effect on the 
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QOL among head and neck cancer patients treated 
with radical radiotherapy at the Kenyatta National 
Hospital, (KNH) in Nairobi. 
 The study was approved by the KNH and 
University of Nairobi    Ethics, Research and Standards 
Committee. 
MATERIALS AND METHODS
The study was carried out in the department of 
radiotherapy of KNH, which is the only public 
hospital in Kenya with a radiotherapy facility serving 
an estimated population of 30 million people. Its 
radiotherapy facility consists of the cobalt 60 external 
beam unit. 
 Between January and March 2006, patients 
who had completed radiotherapy for head and 
neck cancer within one month of the study period 
were consecutively invited to participate in a cross-
sectional study of radiation morbidity and QOL. 
The period was specifically selected to provide an 
estimate of both the acute and cumulative effects of 
radiotherapy. Assessment of the patients’ experience 
of radiation related side effects were made using 
selected items of the head and neck radiotherapy 
questionnaire (HNRQ) translated into Kiswahili. 
The selected items consisted of eight questions 
that covered symptoms related to the domains of 
pain, skin irritation, taste, saliva, chewing, speech, 
swallowing and psychological function. Patients rated 
each symptom on a seven point Linkert-type scale 
with one indicating that a given item was a “great 
deal” of trouble and seven indicating that the item 
was ‘not at all’ troublesome. The overall QOL rating 
for each patient was expressed as the mean of the 
score of the eight questions with the score ranging 
between eight points representing the worst and 56 
points representing the best QOL. The score for each 
domain was the mean of the questions that applied 
to it. A mid-point between the two extremes was 
selected as a critical cut-off point between poor (0-32) 
and good (32-56) QOL experiences. 
 Because of the small numbers, patients’ ages were 
grouped into two categories; those above and those 
below 50 years. Similarly, tumour sites were grouped 
into two: the oral sites for all tumour sites occurring in 
the oral cavity and other sites, for tumours occurring 
in the oropharynx, nasopharynx and larynx. The 
HNRQ was administered by a trained interviewer. 
 Patient and disease characteristics were 
summarised using descriptive statistics and presented 
as means, percentages, medians and ranges. The 
side effects ratings were summarised by percentage 
of the patients scoring above or below the 32 critical 
points value. Comparison between proportions of 
patients scoring above (good QOL) and below (poor 
QOL) the 32-points value was made with respect to 
age, gender and tumour site using Fisher’s exact test 
with a 0.05 significance level and the 95% confidence 
interval. Statistical analysis was carried out using the 
Statistical Package for Social Sciences (SPSS) II for 
Windows (SPSS Inc, Chicago, IL, USA). 
RESULTS
Patients, tumour, and treatment profile: The profile of 
patients, tumours and treatment is shown in Table 
1. Thirty eight patients comprising 28 males and 
10 females aged between 21 and 69 years (Mean 
= 47 ± 13.39) were evaluated. The majority of the 
tumours occurred in the nasopharynx (38.6%). 
The rest of the tumours were divided equally 
between the oral cavity and larynx at 31.6%. All the 
tumours except two were carcinomas. The other 
tumours were a glomus tumour and a malignant 
melanoma. The patients received radiotherapy 
through the cobalt 60 external beam radiation in 
doses ranging between 58.8 Grey and 78.8 Grey 
(Median 70 Grey). Out of the 38 patients 16 (42%) 
had their treatment interrupted on account of 
radiation morbidity. 
 Incidence and degree of debilitation of acute radiation 
morbidity: The occurrence of acute radiation morbidity 
and the degree of debilitation are shown in Table 2. 
The most common side effect was dryness of the 
mouth or xerostomia (92.1%) followed by pain 
and soreness of the mouth, pain and itchiness of 
the skin, hoarseness or loss of voice and difficulty 
in swallowing in almost equal proportions. Other 
symptoms included difficulty tasting food (76.3%), 
anger/depression/fatigue (63.2%) and difficulty 
in chewing (55.3%). Of these symptoms, the one 
considered most troublesome by the majority of the 
patients was difficulty in tasting food (98%). This 
was followed by pain and soreness in the mouth 
(89%), dryness of the mouth (80%) and difficulty in 
swallowing (73%). Pain and itchiness of the skin, 
difficulty in chewing, hoarseness or loss of voice and 
anger/depression/fatigue were considered relatively 
less troublesome. 
Variation in QOL by gender, tumour site and treatment 
interruption: Table 3 shows that there were no 
variations within and between QOL categories by 
age, gender or tumour site. There was, however, a 
significant difference in the QOL among patients 
who had treatment interruption and those who had 
not. Patients who had treatment interruption were 
more likely to have had a better QOL than those 
who had not. 
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Table 1
Patient, tumour and treatment profile 
Characteristic No.  (%) 
Gender 
  Male 28 74
  Female 10 26 
Age 
  Range 21-69
  Mean 47 ± 13.39 
Tumour site 
  Oral cavity 12 31.6   
  Nasopharynx 14 38.8 
  Larynx 12 31.6
Tumour type 
  Cancerous 36 95 
  Glomus tumour 1 2.5
  Malignant melanoma 1 2.5   
Radiation dose (Gy) 
  Range 58.5-75.5 
  Mean 70 
Treatment interruption 
  Yes 16 42.1
  No 22 57.9
Cumulative dose (Gy) 
  Range 20-46 
  Median 35  
Table 2 
Incidence and degree of debilitation of acute radiation morbidity
Symptom Overall frequency   Degree of debilitation (%)
 (%) A great deal  A lot A fair bit Hardly any
     
Pain and soreness in the mouth   86.8 89 10 7 3
Pain and itchiness of the skin 86.8 18 12 65 15
Difficulty tasting food  76.3 98 2 - -
Dryness of the mouth   92.1 80 10 5 5
Difficulty chewing  55.3 25 10 10 55
Hoarseness or loss of voice 86.8 23 15 47 12
Difficulty swallowing  86.8 73 8 5 12
Anger/Depression/Fatigue 63.2 38 10 12 40
Table 3
Variability of QOL by gender, tumour site and treatment interruption
 Overall       Age(%)       Gender (%)    Tumour site     Treatment
 Frequency      (%)     Interruption (%) 
 (%) <50 >50 M F Oral Others Yes No
        cavity
QOL outcome
Good QOL 19 (50) 78.9 21.1 73.3 26.3 15.8 84.2 57.9 42.1
Poor QOL 19 (50) 36.8 63.2 73.3 26.3 47.4 52.6 26.3 73.3
P-value        0.02              1              0.079            0.049
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DISCUSSION
The relative frequencies of the radiation morbidity 
in this study are high but largely similar to those 
reported in other studies (8-11). In the literature the 
most commonly reported radiation side effects are 
mucositis and xerostomia, both estimated at 80% 
(10, 12), skin reaction estimated at 90% (13), pain 
and suffering estimated at 69% (11) and pain on 
swallowing estimated at 56% (14). In the present 
study, 47% of the patients had their treatment 
interrupted on account of radiation morbidity. This 
relatively high incidence, however, is common and 
supports published data which show that about 30 to 
50% of radical treatments are interrupted for various 
reasons (15-21). For example, in a study of patients 
with laryngeal tumours receiving radical therapy 
it was found that only 34% had their treatment 
within the prescribed time, 29% had their treatment 
prolonged by one or two days and 37% had a longer 
interruption (3-15 days) (21). In a related study among 
patients undergoing radiotherapy for head and neck 
cancer at KNH, it was found that 50% of the patients 
completed their treatment within the prescribed 
time, 7.7% had their treatment interrupted by one 
to five days, 58.8% by six to ten days and 38.5% by 
over 10 days (22). However, the prolongation of the 
overall time taken for delivery of a radical course of 
radiotherapy arising from unscheduled interruption 
in the treatment affect cancer control and cure rates 
and should be avoided or compensated for. 
 In the assessment of the impact of radiation 
morbidity on QOL, it was curious that most patients 
found loss of taste to have been more debilitating 
than other side effects, such as pain and dryness of 
the mouth. However, this finding needs to be treated 
with caution because there are possible problems 
associated with translation and misinterpretation of 
the questionnaire, which was developed primarily 
for a culturally different population. It was, however, 
disturbing that despite the severity of symptoms no 
patients received nutritional support. It has been 
estimated that 20-30% of patients undergoing radical 
radiotherapy for head and neck cancer required 
parenteral feeding on account of mucositis (9). In 
patients who are nutritionally compromised, failure 
to provide supplemental feeding during radical 
radiation therapy enormously erodes the prognosis 
and the QOL. 
 In this study the impact of radiation morbidity 
on the QOL did not vary with age, gender or tumour 
site. However, data from studies on the influence 
of age and gender on QOL of cancer patients are 
conflicting. In some studies no gender difference 
was noticed (23) whereas in others a worse QOL 
was reported for women (24 - 26). Similarly, in some 
studies no influence of age on QOL was found (27) 
while in others better QOL was found among younger 
patients (28). Although not apparent in our study, 
tumour site has been reported as having a definite 
influence on the QOL among head and neck cancer 
patients (29). Patients with pharyngeal cancer have 
been shown to suffer more severe morbidity and to 
have a poorer QOL as opposed to those with oral or 
laryngeal cancer (29). The apparent lack of variation of 
the QOL with tumour site in our study was probably 
due to the relatively small sample size.
 The difference in the QOL between patients 
who had and those who did not have treatment 
interruption is understandable. The period of rest 
provided by treatment interruption allowed patients 
to recover from side effects as opposed to those who 
did not. However, while the patients may have felt 
better, their prognosis may have been severely eroded 
by treatment interruptions. An ideal treatment should 
aim at reducing the side effects without compromising 
prognosis. 
In conclusion, this study provides information that 
should help in communicating with head and neck 
cancer patients undergoing radical radiotherapy 
and in the design of preventive and interventional 
strategies aimed at enhancing patient support and 
rehabilitation. 
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